[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345337-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345337-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","hereditary-diffuse-gastric-cancer-spectrum-associated-with-germline-ctnna1-loss-of-function-revealed-by-clinical-and-molecular-data-from-351-carrier-families-and-over-37-000-non-carrier-controls","Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls","","Diffuse gastric cancer (DGC) is a common manifestation among germline CTNNA1 variant carriers, yet understanding of CTNNA1-related hereditary diffuse gastric cancer (HDGC) remains limited, including loss-of-function mechanisms, variant-type causality, disease spectrum, and cancer risks. This study explores CTNNA1 genotype–phenotype links using clinical, molecular, and population data from carrier families and non-carrier controls, supported by CRISPR/Cas9 and Drosophila functional models, to refine genetic testing, surveillance, and risk-reduction guidance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/hereditary-diffuse-gastric-cancer-spectrum-associated-with-germline-ctnna1-loss-of-function-revealed-by-clinical-and-molecular-data-from-351-carrier-families-and-over-37-000-non-carrier-controls/345337/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/hereditary-diffuse-gastric-cancer-spectrum-associated-with-germline-ctnna1-loss-of-function-revealed-by-clinical-and-molecular-data-from-351-carrier-families-and-over-37-000-non-carrier-controls/345337.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the primary focus of this study on CTNNA1 and gastric cancer?","Question",{"text":63,"@type":64},"The study examines genotype–phenotype associations for CTNNA1 to improve genetic testing criteria, surveillance, and risk-reduction recommendations for carriers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which mechanism is implicated for CTNNA1 truncating variants?",{"text":68,"@type":64},"CTNNA1-truncating transcripts are degraded by nonsense-mediated mRNA decay (NMD), leading to loss of αE-catenin in diffuse gastric cancers.",{"name":70,"@type":61,"acceptedAnswer":71},"How do cancer risks compare between CTNNA1 truncating and non-truncating carriers?",{"text":72,"@type":64},"DGC risk is eightfold higher in truncating versus non-truncating carriers, and risks for gastric cancer and lobular breast cancer development are reported as fivefold and eightfold lower than in CDH1, respectively.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345337,1790180540,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","GI cancer  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.1136/gutjnl-2024-334601](10.1136/gutjnl-2024-334601)) .  \nFor numbered affiliations see end of article.  \nCorrespondence to  \nProfessor Carla Oliveira; [carlaol@i3s.up.pt](carlaol@i3s.up.pt)  \nReceived 16 December 2024 Accepted 21 August 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \nTo cite: Lobo S, Dias A, Pedro AM, et al. Gut Epub ahead of print: [please include Day Month Year] . doi:10.1136/ gutjnl-2024-334601  \nOriginal research  \nHereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls  \nSilvana Lobo  , 1,2 Alexandre Dias, 1,2 Ana Maria Pedro, 1 Marta Ferreira, 1,3  \nAndré Pinto-Oliveira,1 Celina São José  , 1 Jennifer Herrera-Mullar,4 Nádia Pinto, 1,5 Chrystelle Colas  ,6,7 Robert Hüneburg  ,8,9 Jacob Nattermann  ,8,9  \nLise Boussemart, 10 Liselotte P van Hest, 11 Leticia Moreira  , 12,13 Carolyn Horton,4 Dana Farengo Clark, 14 Sigrid Tinschert, 15 Lisa Golmard,6 Isabel Spier,9,16  \nAdriá López-Fernández,17 Daniela Oliveira, 18 Magali SVRCEK, 19 Pierre Bourgoin,20 Florence Coulet,21 Hélène Delhomelle,6,22 Jeremy Davis  ,23 Birthe Zäncker,24 Conxi Lazaro,25,26 Joana Guerra,27,28 Maria L Almeida,29 Sergio Carrera,30 Ana Patiño,31,32 Paul Gundlach,33 Monika Laszkowska,34,35 Vivian E Strong,36 Manuel R Teixeira,2,27 Intan Schrader  ,37 Verena Steinke-Lange,38 Irene Gullo, 1,39,40 Sérgio Sousa, 18 Manuela Batista,41 Stefan Aretz,9,16 Judith Balmaña, 17,42  \nMelyssa Aronson,43 Augusto Perazzolo Antoniazzi,44 Edenir I Palmero,45,46  \nPaul Mansfield,47 Lizet E van der Kolk,48 Annemieke Cats,49 Jolanda M van Dieren,49 Sergi Castellví-Bel, 12 Bryson Katona, 14 Rachid Karam,4 Paulo S Pereira, 1,50  \nPatrick R Benusiglio,21 Carla Oliveira  1,40,51  \nABSTRACT  \nBackground Diffuse gastric cancer (DGC) is the most common manifestation in germline CTNNA1 variant carriers, with one study estimating a 49–57% lifetime risk by age 80. Knowledge on CTNNA1-associated hereditary diffuse gastric cancer (HDGC), loss-of-function mechanisms, variant-type causality, disease spectrum and cancer risks remains scarce.  \nObjective Explore CTNNA1 genotype–phenotype associations to improve genetic testing criteria, surveillance and risk-reduction recommendations for carriers.  \nDesign Using molecular, clinical and population data from 1308 individuals from 351 CTNNA1-variant carrier families and 37 428 non-carriers from European and American ancestries, we analysed genotype–phenotype associations with multivariable logistic regression. With CRISPR/Cas9 CTNNA1-knockout gastric cancer (GC) cells and CTNNA1-humanised Drosophila, we assessed CTNNA1-associated loss-of-function mechanisms. Results CTNNA1-truncating transcripts are degraded by nonsense-mediated mRNA decay (NMD), and DGCs from germline CTNNA1-truncating carriers lose αE-catenin. These transcripts are non-functional in Drosophila, in contrast to non-truncating transcripts. DGC risk is eightfold higher in truncating, compared with nontruncating carriers. The risk of GC and lobular breast cancer (LBC) development in CTNNA1-truncating variant carriers is fivefold and eightfold lower than in CDH1  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n⇒ CTNNA1 germline variants were accepted as predisposing to hereditary diffuse gastric cancer (HDGC) based on the report of 13 families.  \n⇒ Current knowledge is very limited regarding CTNNA1-associated loss-of-function mechanisms, variant-type causality, disease spectrum and cancer risks, which hampers defining the clinical management of CTNNA1 variant carrier individuals and families.  \npathogenic/likely pathogenic variant carriers, respectively. Com","cbCaiv8lABbl0ZbG","https://ap.wps.com/l/cbCaiv8lABbl0ZbG","pdf",5105360,14,"English","# Abstract\n## Background\n## Objective\n## Design\n## Results\n## Conclusion\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What is the primary focus of this study on CTNNA1 and gastric cancer?\",\"answer\":\"The study examines genotype–phenotype associations for CTNNA1 to improve genetic testing criteria, surveillance, and risk-reduction recommendations for carriers.\"},{\"question\":\"Which mechanism is implicated for CTNNA1 truncating variants?\",\"answer\":\"CTNNA1-truncating transcripts are degraded by nonsense-mediated mRNA decay (NMD), leading to loss of αE-catenin in diffuse gastric cancers.\"},{\"question\":\"How do cancer risks compare between CTNNA1 truncating and non-truncating carriers?\",\"answer\":\"DGC risk is eightfold higher in truncating versus non-truncating carriers, and risks for gastric cancer and lobular breast cancer development are reported as fivefold and eightfold lower than in CDH1, respectively.\"}]","Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls | PDF",1790057330,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4a845f5b39dd807d292a8f4e6bdc49ce.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd16b5836ed7ab56585fe30840968762.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/054352579917f0365fe453402e83aba8.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8bb02330c943df225d43a707afb19f9.webp",980,1306]